Regenerative Medicine Market measure with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast till 2026

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (Market Insight Reports) —
The latest report on ‘Regenerative Medicine market’ collated by Market Study Report, LLC, delivers facts and numbers regarding the market size, geographical landscape and profit forecast of the ‘Regenerative Medicine market’. In addition, the report focuses on major obstacles and the latest growth plans adopted by leading companies in this business.

Request a sample Report of Regenerative Medicine Market at: https://www.marketstudyreport.com/request-a-sample/1695290?utm_source=marketwatch&utm_medium=RV

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.

The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

Enquiry about Regenerative Medicine market report before Buying at: https://www.marketstudyreport.com/enquiry-before-buying/1695290?utm_source=marketwatch&utm_medium=RV

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

Purchase full report of Regenerative Medicine market at: https://www.marketstudyreport.com/securecheckout/paymenta/1695290?utm_source=marketwatch&utm_medium=RV?msfpaycode=sumsf

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.

Regenerative Medicine Market share

Read more

Gulf Medical University College of Medicine and ScholarRx Announce Medical Education Partnership

LOUISVILLE, Ky., Dec. 2, 2020 /PRNewswire/ — Today the Gulf Medical University College of Medicine (GMU) and ScholarRx announced a collaboration to further the College’s educational mission. GMU has adopted the Rx Bricks online service from ScholarRx, a revolutionary digital learning platform that supports the curriculum and enhances pre-clinical instruction.

ScholarRx (PRNewsfoto/ScholarRx)

Prof. Hossam Hamdy, Chancellor, Gulf Medical University states, “Gulf Medical University’s partnership with ScholarRx ensures that the content of the medical curriculum is benchmarked with similar top U.S. medical colleges using the same program. The Rx Bricks of ScholarRx provide our students with up-to-date medical knowledge through educationally sound courses delivered by expert faculty. As a leading medical university in the Middle East, Gulf Medical University will contribute to the continuous development of ScholarRx by integrating its Virtual Patient Learning (VPL) technology in the Rx Bricks, conducting research, and evaluating the educational impact of ScholarRx.  I am sure our students and faculty will appreciate the value of ScholarRx.” 

GMU uses the innovative Rx Bricks digital learning platform from ScholarRx to better engage and align medical students with the curriculum. This has become especially important as more learning is taking place online. With this new set of resources, faculty teaching GMU students can:

  • Assign specific Rx Bricks through their learning management system
  • Use question banks accompanying the Rx Bricks for both formative and summative assessments, and
  • Provide foundational support to their virtual patient learning sessions.

“Collaboration with ScholarRx has enriched and added value to our existing online learning resources, as the College of Medicine has been able to seamlessly integrate the Rx Bricks in the medical curriculum. Faculty and students alike have embraced it with ease due to the user-friendly nature of the resource,” said Prof. Manda Venkatramana, Vice-Chancellor Academics and Dean, College of Medicine at Gulf Medical University.

“GMU has developed into a leading institution for medical education in the Middle East under the visionary leadership of Chancellor Hamdy and Vice-Chancellor Manda,” said Dr. Tao Le, Founder and CEO of ScholarRx. “We are pleased to support their remarkable work in digital curricular innovation.”

About Gulf Medical University College of Medicine
The vision of the university is to be a leading international academic healthcare institution through the integration of quality health professions education, research, healthcare, and social accountability for sustainable community development. The College of Medicine, in existence since 1998, has managed to not only impart quality medical education, but has also created a network of healthcare services, a conducive research milieu, and developed unique related avenues for professional development, policy, and leadership to meet the healthcare needs of the nation and the region.

About ScholarRx
ScholarRx is a mission-driven education organization currently serving over 150,000 medical students and physician learners annually.  ScholarRx has developed a revolutionary componentized, multi-competency curricular platform that empowers medical schools and their faculty to rapidly develop high-quality education experiences, even in resource-poor environments.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gulf-medical-university-college-of-medicine-and-scholarrx-announce-medical-education-partnership-301183960.html

SOURCE ScholarRx

Source Article

Read more

The 9 top health and medicine breakthroughs of 2020

Despite the upheaval the coronavirus pandemic has brought, uneasy times also set a course for innovation. Pharmaceutical companies have pivoted to vaccine development, while biotechnology laboratories at major corporations and universities have become laser-focused on developing accurate testing devices, including an easy-to-use, fast, reliable, and extremely cheap test for COVID-19; personal protective equipment, like a prototype for a reusable N95 mask; and technologies to ensure people have access to the best possible medical care during trying times. And in spite of these difficult days, better treatments for existing challenges such as myopia, migraines, sleep apnea, and acne have prevailed, helping this year’s top health advances provide the glimmer of hope we all need.



a screenshot of a video game remote control: The year's most important developments in the world of health.


© Provided by Popular Science
The year’s most important developments in the world of health.



The BinaxNOW COVID-19 test displays a positive result within 15 minutes.


© Provided by Popular Science
The BinaxNOW COVID-19 test displays a positive result within 15 minutes.

Grand Award Winner: BinaxNOW COVID-19 Ag Card rapid antigen test by Abbott Laboratories

A fast, ultra-cheap coronavirus test

Diagnostic tests to detect SARS-CoV-2, the virus that causes COVID-19, can take days to deliver results. But that limbo time between is crucial. Spotting the novel virus as early as possible can signal infectious people to isolate themselves, and help contact tracers identify and notify anyone they’ve been in close quarters with. Since March, countless new offerings to evaluate the population’s infection rates have hit clinics, but one rises above the rest: Abbott’s BinaxNOW rapid test, which received emergency-use authorization from the FDA in August. It detects COVID in fifteen minutes for around $5 per test—and without the need for specialized lab equipment.

To administer the test, a healthcare worker opens a card—which is about the size of a driver’s license—and adds a few drops of a liquid called a reagent. That solution contains chemicals that react with the SARS-Cov-2 nucleocapsid antigen, which is the most abundant coronavirus protein in infectious individuals. Then, using an included swab, the provider takes a nasal sample, inserts it into the card, and folds the paper. A positive result—displayed as two pink lines on the outside of the card—will become evident in about 15 minutes. The system correctly identifies patients with the novel virus 97.1 percent of the time, on average, and provides an accurate negative test 98.5 percent of the time, making it a reliable and speedy assessment of COVID-19.



a close up of a device: Aklief is the first novel retinoid cream in more than 20 years.


© Provided by Popular Science
Aklief is the first novel retinoid cream in more than 20 years.

Aklief cream by Galderma Laboratories, L.P.

A retinoid acne product that’s easier on your skin

Acne vulgaris (meaning “common”) affects up to 85 percent of teens and young adults in the US, according to a 2013 study in the British Journal of Dermatology. A regularly used group of medications called retinoids help alleviate the condition by binding to retinoic acid receptors (RAR) on the skin’s surface, which in turn stimulate and speed up cell growth, causing old cells to rapidly shed and give way to newer, healthier ones. But this process often leads

Read more

Former Barrie surgeon agrees not to practise medicine again, anywhere

A former Barrie surgeon has given up his licence to practise medicine and has promised his regulatory body to never apply to register as a physician ever again, anywhere.

The agreement arose following a College of Physicians and Surgeons of Ontario (CPSO) disciplinary hearing last week.

“The agreement to never reapply for registration… is the maximum level of punishment available in this situation,” said CPSO communications advisor Josh McLarnon.

The college had earlier launched investigations into Dr. Emad M. Guirguis and his now-defunct Lakeview Surgery Centre on Dunlop Street following complaints.

He was found to perform cosmetic surgery that was outside his scope of practice as a physician, not having the proper training and certification.

He also engaged in unprofessional conduct through online advertising and communications with a specific patient.

In addition to the practice ban, he was ordered to pay $6,000.

“Dr. Guirguis has been brought forward to the discipline committee on a number of occasions,” McLarnon added.

An investigation was first launched in 2015 resulting in a caution three years later.

Another caution was later issued relating to his compliance of the first issue.

In one complaint, Guirguis tried to perform bariatric revision gastric band surgery, but decided not to complete the surgery because he encountered extensive scar tissue from previous surgeries. According to documents from the college’s compliance and monitoring department, he perforated the patient’s bowel during the surgery, resulting in ongoing complications.

The complainant said he did not communicate or follow up with her after the surgery or provide a refund of her fee.

“The committee… was of the view that the respondent’s pre-operative assessment was insufficient,” the decision of the inquiries, complaints and reports committee found.

In another report, an independent assessor concluded: “Dr. Guirguis did not meet the standard of practice of the profession in some of the cases reviewed; his knowledge was adequate but basic; his surgical skills were adequate for his limited scope of practice; his judgment was not always adequate, mostly because the brief documentation does not allow a full understanding of his train of thought and exposes omissions or incomplete assessments; and in the reviewed cases his clinical practice, behaviour, or conduct had the potential to expose one patient to harm.”

Other assessors, it added, found broad deficiencies in Dr. Guirguis’s practice.

In a report from Dec. 14, 2018, Guirguis was cautioned about not providing a full explanation of a procedure to a patient and ensuring the patient had full clarity about what was going to be done following a complaint to the college about the outcome of a cosmetic surgical procedure.

According to CPSO documents, Guirguis agreed he has engaged in an act or omission relevant to the practice of medicine that would reasonably be regarded by members as disgraceful, dishonourable or unprofessional.

He was ultimately found to have committed an act of professional misconduct.

Loading…

Loading…Loading…Loading…Loading…Loading…

Dr. Guirguis’s certificate of registration expired Sept. 4, 2020.

In addition to the clinic, Guirguis was also once

Read more

How to Reap the Benefits of Food as Medicine

Development & Aid, Featured, Food & Agriculture, Food Security and Nutrition, Food Sustainability, Global, Headlines, Health, Humanitarian Emergencies, Inequity, TerraViva United Nations

Sorghum is has nutritional and health benefits. Small scale farmer, Catherine Sibanda examines her sorghum crop in field, in Jambezi District, Zimbabwe, March 2015. Credit: Busani Bafana / IPS

BULAWAYO, Dec 2 2020 (IPS) – COVID-19 has magnified global food insecurity and is driving unhealthy eating and worsening malnutrition, food experts say. They have called for deliberate global investment in food as medicine on the back of growing diet-related illnesses.

Famed Greek physician, Hippocrates, foretold the future of food. He is attributed to have said: ‘Let food be thy medicine and let medicine be thy food’. COVID-19 has pushed the conversation about food as medicine onto the world agenda as more people are paying attention to their health and increasingly what they eat.

“COVID 19 has exposed American population to infectious diseases, and it has started off the conversation around food is medicine and how we need to reset our food system to create higher quality and more nutrient-dense food,” physician and author, Mark Hyman, told a plenary session at the virtual ‘Resetting the Food System from Farm to Fork’ dialogue co-hosted by the Barilla Centre for Food and Nutrition (BCFN) and Food Tank.

Hyman said a rejigged food system which creates better health for the population was a good strategy for pandemic resistance. He said food as medicine is part of medical care because it works better and faster and cheaper than most drugs and is probably the most effective treatment we have for most chronic illnesses.

“Science is clear that more nutrient density and food quality plays a huge role in human health and the protector foods, foods that protect you against disease and have medicinal properties,” said Hyman. He proposed the eating of more inexpensive, plant-based foods. “We need to rethink farming and introduce more nutrient-dense foods.”

Early this year, the United Nations warned that the pandemic would escalate a global food crisis – the worst in 50 years. The international body said the pandemic would make nutrition beyond the reach of many.

“Our food systems are failing, and the COVID-19 pandemic is making things worse,” UN Secretary-General, Antonio Guterres, warned, proposing three action plan to bolster a failing food system.

Guterres said countries should designate food and nutrition services as essential while implementing protections for those who work in the sector, prioritise food supply chains and strengthen social protection for young children, pregnant and breastfeeding women, older people and other at-risk groups. He also advocated the transformation of food systems for a more inclusive and sustainable world.

More than 820 million people in the world do not have enough to eat even though there is plenty of food to feed everyone. Globally, some 144 million children under five years are stunted as a result of malnutrition.

The UN has warned that nearly 690 million people, or 8.9 percent of the world’s population, were undernourished

Read more

QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND – Press Release

CAMBRIDGE, Mass.–(Business Wire)–QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced that the company will present two posters featuring data from two of the company’s preclinical precision medicine ALS programs at the Motor Neuron Disease Association (MNDA) 31st International Symposium on ALS/MND, being held virtually on December 9-11, 2020.

QurAlis co-founders and Harvard professors Kevin Eggan, Ph.D. and Clifford Woolf, M.D., Ph.D., members of the QurAlis Scientific and Clinical Advisory Boards, Brian Wainger, M.D., Ph.D. (Massachusetts General Hospital) and Merit Cudkowicz, M.D., M.Sc. (Massachusetts General Hospital), and other authors recently published in JAMA Neurology the results of a clinical study investigating the therapeutic potential of Kv7 agonism in ALS. The clinical data support QurAlis’ belief that a safe Kv7 opener could be an effective disease-modifying therapy for ALS patients with motor system hyperexcitability, an approach that QurAlis is pursing with its preclinical program investigating the regulation of the Kv7.2/7.3 ion channel.

The poster presentations will share, for the first time publicly, results from preclinical studies of QurAlis’ program investigating a novel Kv7.2/7.3 ion channel agonist as a potential treatment for motor neuron hyperexcitability and excitotoxicity, as well as its program targeting the TBK1 autophagy pathway.

“While KV7 agonists have shown great potential as a treatment for the 20-50% of ALS patients who present with hyperexcitability in their motor system, they can often cause undesired side effects such as dizziness and fatigue,” said Daniel Elbaum, Ph.D., Chief Scientific Officer of QurAlis. “The preclinical data we will be presenting show that the improved channel specificity of our novel Kv7.2/7.3 agonist could translate into an improved clinical safety profile with significant reduction in off-target adverse events. We look forward to sharing the full results of this preclinical study as well as discussing our autophagy program at the MNDA 31st International Symposium on ALS/MND.”

Details of the presentations are as follows:

Title: TBK1 Autophagy Pathway Disease Mechanisms in ALS

Authors: Erika Norabuena; Clinton Bourbonais; Kasper Roet, Ph.D.; Kevin Eggan, Ph.D.; Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.

Presenting Author: Erika Norabuena

Date/Time: December 9, 2020, 12:10pm-12:50pm ET

Poster/Abstract Number: TST-07

Link to abstract

Title: QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients

Authors: Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.; Kasper Roet, Ph.D.

Presenting Author: Daniel Elbaum, Ph.D.

Date/Time: December 11, 2020, 7:05am-7:50am ET

Poster/Abstract Number: TST-20

Link to abstract

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord. ALS breaks down nerve cells, reducing muscle function and causing loss of muscle control. ALS can be traced to mutations in over 25 different genes and is often caused by a combination of multiple sub-forms of the condition. Its average life expectancy is three years, and there is currently no cure for the disease.

About QurAlis Corporation

QurAlis is bringing hope to the

Read more

Want to understand Trump’s die-hard fans? Look to alternative medicine.

How is this possible, asks the weary majority of Americans who accept Joe Biden’s win? Despite disavowals of fraud from one conservative election official after another? Despite a complete lack of evidence?

To understand them, it’s helpful to turn to an unlikely parallel: the world of wellness, natural health and alternative medicine. It’s a world of unsolved medical conditions, chronic illness, suffering for which the establishment has no answers. Often that suffering is looked down upon or dismissed, leaving patients alienated and ripe for exploitation. Uncertain and angry, they need a new system to make sense of their situation and give them hope.

Where Trump’s favored enemy is mainstream media, alternative-health gurus rail against mainstream medicine. Both paint their opponents as deeply evil propagandists who quash truth by censoring it. All standard sources of evidence become suspect. Strangely, this widespread evil is a source of clarity and hope. Your suffering has an easy resolution, if only “they” would allow it.

The parallels are unmistakable. Consider these lines from a 2020 Trump speech:

“The radical left demands absolute conformity from every professor, researcher, reporter. … Anyone who dissents from their orthodoxy must be punished, canceled, or banished.”

“Modern-day ‘science’ demands absolute obedience and conformity to industry claims; all dissenters must be silenced and punished.”

In both, basic consensus on facts is evidence of sinister conformity. According to this logic, losing one’s credibility or position for insisting on falsehoods is evidence of heterodox heroism.

With authorities discredited, Trump and the gurus encourage their followers to feel as if they have figured things out for themselves instead of submitting to the decrees of mainstream experts. This allows them to provide the same existential prescription: empowerment and freedom. Those who take mainstream medicine are “sheeple,” and so are those who believe in mainstream media. “The sheeple have got to be led,” explains one Trump supporter. “If you go out and look for alternative media sources, you get the truth.” (All cults exploit the empowering thrill of discovering occult knowledge: “Do your own research” is a mantra in the fringes of alternative health and within the QAnon conspiracy theory — a shared foundation that demystifies the seemingly bizarre overlap between the two communities.)

Like Trump, alternative-medicine gurus are frequently inconsistent. They will decry mainstream institutions and elites as hopelessly corrupt, and then they triumphantly cite a study from Harvard University or an article from this newspaper as their evidence. But supporters do not care about consistency. What matters instead is the rush of empowerment that makes the passive patient a powerful actor. “Take control of your health,” promises Joseph Mercola, the owner of an influential natural-medicine website. (Each article on the site comes with its own “Fact Checked” certification.) “Own Your Body, Free Your Mind” says Kelly Brogan, a popular “holistic psychiatrist.”

The ideological overlap of alternative medicine and Trump’s philosophy explains why the following lyrics, rapped by two Trump supporters at the “Million MAGA March,” include a reference to vaccines alongside standard political conspiracism:

Read more

Faculty of Medicine Siriraj Hospital wins prestigious award for “Building a Secure, Reliable and Smart 5G Hospital in Thailand”

Faculty of Medicine Siriraj Hospital wins prestigious award for “Building a Secure, Reliable and Smart 5G Hospital in Thailand”

Prof. Dr. Prasit Watanapa (left), Dean of Faculty of Medicine Siriraj Hospital, receives the CommunicAsia Award from Mr. Sanchai Noombunnam (right), Deputy Managing Director of Informa Markets Thailand.

Prof. Dr. Prasit Watanapa, Dean of Faculty of Medicine Siriraj Hospital, received the CommunicAsia Awards 2020, in the “Most Innovative 5G Trial in APAC” category from Mr. Sanchai Noombunnam, Deputy Managing Director of Informa Markets Thailand, during the “5G Powered Smart Hospital Enabled with Cloud and AI” MoU signing ceremony between the Faculty of Medicine Siriraj Hospital and Huawei Thailand.

The distinguished award celebrates the hospital’s achievement in integrating Huawei’s 5G+Cloud+AI COVID-19 diagnosis solution into the hospital’s operations to enhance the efficiency of coronavirus diagnosis and treatment throughout the pandemic. The solution significantly helps the medical staff shorten the wait time of COVID-19 results, while providing a high-speed connection with low latency during remote operations, thanks to the fifth-generation network. The cloud-based system also improved patients’ data collection and resource allocation. Huawei’s tailor-made solutions have proven effective in reducing the workload of medical personnel and helping the country better control the pandemic. 

The award celebrates a fruitful partnership between Siriraj Hospital and Huawei Thailand, under the “Building a Secure, Reliable and Smart 5G Hospital in Thailand” project, that resulted in a revolutionary COVID-19 diagnosis and treatment solution leveraging on the power of 5G, Cloud and AI technology.

The award also recognises the success of the “5G unmanned medicine delivery vehicle” pilot project, developed by Huawei in collaboration with the National Broadcasting and Telecommunications Commission (NBTC) and the Faculty of Medicine Siriraj Hospital. The 5G driverless vehicle aims to reduce personnel contact, minimise infection risks, and improve drug delivery efficiency in the new medical era. 

“I am deeply honoured to receive this award on behalf of the hospital. At Siriraj, we always look for ways to improve efficiency of medical services and operations,” said Prof. Dr. Prasit Watanapa during his acceptance speech. “I would like to thank Huawei for its continuous support in helping us realise our vision for a 5G smart hospital. We will continue to jointly explore new opportunities in the 5G healthcare field. Together we will bring reliable and efficient medical services to the Thai people.”

“This is a proud moment for the Hospital, and we are delighted to have contributed to this honour,” said Huawei Thailand CEO Mr. Abel Deng. “It is Huawei’s mission to accompany Thailand as it develops a strong, connected healthcare ecosystem through 5G and other advanced technologies and solutions.”

Source Article

Read more

‘Heart-breaking’: 30,000 sign petition urging Pharmac to fund inflammatory bowel disease medicine

It is too late for Hayley Greer.

The 24-year-old from Lower Hutt had surgery to remove her colon in January, after medicine for her inflammatory bowel disease stopped working. She will live with an ostomy bag for the rest of her life.

She joined dozens of protestors on a march through Wellington’s streets on Wednesday afternoon to present a 30,000 signature petition to Parliament calling on Pharmac to fund ustekinumab, a medicine used to treat bowel disease.

More than 20,000 New Zealanders live with diseases such as Crohn’s or colitis but if the funded drugs don’t work, or for only a limited time, there are no other options but surgery.

READ MORE:
* Mum says ‘miracle’ drug saved ill baby Kaan Hunter’s life
* Stage four cancer sufferer ‘beyond thrilled’ at Pharmac funding life-extending drug Ibrance
* A year of running: From a hospital bed to a marathon

Hayley Greer, 24, says she may not have needed major surgery if ustekinumab was funded in New Zealand.

ROBERT KITCHIN/Stuff

Hayley Greer, 24, says she may not have needed major surgery if ustekinumab was funded in New Zealand.

“If it was funded it could’ve prevented me having to have my colon out. It could’ve prevented my whole surgery,” Greer said.

“That is really hard to process.”

Ustekinumab is funded in more than 35 countries overseas. Without the expensive treatment, doctors condemn patients to a life of unnecessary pain, Crohn’s and Colitis NZ chair Richard Stein said.

“When people don’t respond to medication we have nothing left except surgery. The disease also comes back,” he said.

Marian O’Connor, co-chair of the Inflammatory Bowel Disease nurses group said nurses found it “frustrating, heartbreaking and soul-destroying” to tell young patients they needed to have major surgery.

People are most commonly diagnosed with Crohn’s or colitis as teens or young adults.

“Sitting with a 17-year-old girl explaining that her bowel is going to be removed and that she will have to live the rest of her life with a stoma bag is heartbreaking,” she said.

Pharmac’s own committee advised that it fund ustekinumab in May. Its chief executive Sarah Fitt told protestors she had regular discussions with suppliers and hoped the medicine would be funded soon. The drugs were on a waiting list.

Chair Steve Maharey said they would “do their best” to get the medicine funded.

Jessica Port, 34, (right) from Porirua was the last person in the country to get ustekinumab on compassionate grounds, and wants others to have the same opportunity.

ROBERT KITCHIN/Stuff

Jessica Port, 34, (right) from Porirua was the last person in the country to get ustekinumab on compassionate grounds, and wants others to have the same opportunity.

“I want to reassure you these issues are in the top of our mind. We would like to solve them and will do our best to solve them,” he said.

“I know these are difficult moments. We would love to give you [a resolution]. We are going to try our best.”

But the words are of little comfort to Greer, who underwent life-altering surgery in January and has been in-and-out of hospital since then.

She was diagnosed in 2014, as a first-year university student. She had two years in remission before the disease came back. Towards the end

Read more

Personalized Medicine Market 2020 Research Report by Size, Revenue, Opportunities, COVID-19 Impact, Status and Outlook to 2024 | Absolute Reports

The MarketWatch News Department was not involved in the creation of this content.

Dec 02, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

Global “Personalized Medicine Market” forecast 2020-2024 is a historical overview and in-depth study on the present and upcoming market of the Personalized Medicine industry. The report represents a basic overview of the Personalized Medicine market size, share, and competitor segment with a basic introduction of manufactures, geographical regions, product types, and applications. This report gives a historical overview of the Personalized Medicine market trends, growth, revenue, capacity, cost structure, and key driver’s analysis.

About Personalized Medicine:

Individualized medication, medication “vary from person to person” , give full consideration to each patient’s genetic factors, gender, age, body weight, physiological and pathological characteristics, and are taking other drugs on the basis of the comprehensive situation of safe, reasonable, effective and economic drug treatment.

Get a Sample Copy of the Report – https://www.absolutereports.com/enquiry/request-sample/14684359

Personalized Medicine Market Segment by Manufacturers, this report covers:

● Abbott Laboratories ● Agilent Technologies ● Amgen ● Astellas Pharma ● Astrazeneca ● Bayer AG ● Celgene Corporation ● Glaxosmithkline Plc ● Illumina ● Johnson and Johnson ● Laboratory Corporation ● Merck ● Novartis AG ● Roche Holding AG ● Siemens AG ● Takeda Pharmaceutical Company Limited

Market Segment by Regions, regional analysis covers:

● North America (United States, Canada and Mexico) ● Europe (Germany, France, UK, Russia and Italy) ● Asia-Pacific (China, Japan, Korea, India and Southeast Asia) ● South America (Brazil, Argentina, Colombia etc.) ● Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers:

● Personalized Medicine Diagnostics ● Personalized Medical Care ● Personalized Medicine Therapeutics ● Personalized Nutrition and Wellness

Market Segment by Applications, can be divided into:

● Oncology ● Central Nervous System (CNS) ● Immunology ● Respiratory ● Other Applications ● Personalized MedicinePersonalized Medicine

To Understand How Covid-19 Impact Is Covered in This Report – https://www.absolutereports.com/enquiry/request-covid19/14684359

Scope of this report:

● The global Personalized Medicine market is expected to reach significant USD by the end of 2024. ● The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions. ● North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Personalized Medicine. ● Europe also play important roles in global market, with market size of significant USD in 2019. ● This report studies the Personalized Medicine market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Personalized Medicine market by product type and applications/end industries.

The content of the study subjects includes a total of 15 chapters:

● Chapter 1, to describe Personalized Medicine product scope, market overview, market opportunities, market driving force and market

Read more